Drug Trial Radar · NCT02338960
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
714
Actual
Start
Jan 2015
Primary completion
Aug 2016
Study completion Jun 29, 2017
Sponsor
- Lead sponsor
- Palatin Technologies, IncIndustry
- Sponsor type
- Industry
- Collaborators
- AMAG Pharmaceuticals, Inc.
- First posted
- Jan 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
Conditions
- Hypoactive Sexual Desire Disorder
Interventions
BremelanotideDrug
A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
- Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Locations
91 sites in 2 countries. Site status is shown where the registry gives one.
Palatin Clinical Site 242
Birmingham, Alabama
Palatin Clinical Site 218
Phoenix, Arizona
Palatin Clinical Site 254
Tucson, Arizona
Palatin Clinical Site 207
Hot Springs, Arkansas
Palatin Clinical Site 258
Beverly Hills, California
Palatin Clinical Site 256
Garden Grove, California
Palatin Clinical Site 291
Los Angeles, California
Palatin Clinical Site 270
Oakland, California
Palatin Clinical Site 210
San Diego, California
Palatin Clinical Site 251
San Diego, California
Palatin Clinical Site 272
Sherman Oaks, California
Palatin Clinical Site 253
Tarzana, California
Palatin Clinical Site 212
Denver, Colorado
Palatin Clinical Site 219
Denver, Colorado
Palatin Clinical Site 243
Lakewood, Colorado
Palatin Clinical Site 211
New London, Connecticut
Palatin Clinical Site 229
Waterbury, Connecticut
Palatin Clinical Site 202
Washington D.C., District of Columbia
Palatin Clinical Site 204
Aventura, Florida
Palatin Clinical Site 273
Coral Gables, Florida
Palatin Clinical Site 203
Fort Myers, Florida
Palatin Clinical Site 255
Gainesville, Florida
Palatin Clinical Site 266
Gainesville, Florida
Palatin Clinical Site 224
Jupiter, Florida
Palatin Clinical Site 250
Orlando, Florida
Palatin Clinical Site 261
Oviedo, Florida
Palatin Clinical Site 260
Pinellas Park, Florida
Palatin Clinical Site 236
West Palm Beach, Florida
Palatin Clinical Site 248
Alpharetta, Georgia
Palatin Clinical Site 263
Atlanta, Georgia
Palatin Clinical Site 288
Addison, Illinois
Palatin Clinical Site 252
Chicago, Illinois
Palatin Clinical Site 201
Chicago, Illinois
Palatin Clinical Site 277
Indianapolis, Indiana
Palatin Clinical Site 247
Prairie Village, Kansas
Palatin Clinical Site 286
Paducah, Kentucky
Palatin Clinical Site 279
Lake Charles, Louisiana
Palatin Clinical Site 281
Metairie, Louisiana
Palatin Clinical Site 257
Annapolis, Maryland
Palatin Clinical Site 222
Lutherville, Maryland
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.